Home / News / Pearce IP Blog
20 Jun 22 | CN | NMPA approves Innovent’s TYVYT® (sintilimab injection) Innovent Biologics and Eli Lilly announced...
11 Jun 22 | Samsung Bioepis presents Ph III eculizumab data Samsung Bioepis presented data from its Ph III trials of...
02 Jun 22 | Civica selects Profil as clinical trial partner for affordable insulin initiative Civica announced that is...
24 May 22 | BR | Shanghai Henlius Biotech signs license agreement for rituximab and trastuzumab biosims Shanghai...
20 May 22 | EU | Prestige Biopharma (Roche/Genentech) | HD201, trastuzumab (Herceptin®) Prestige’s trastuzumab...
16 May 22 | Alvotech (Janssen) | AVT04, ustekinumab, (Stelara®)Alvotech announces study results for AVT04, biosimilar...
04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...
Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...
29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with...
Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...
Introduction Medicinal cannabis is now widely available in Australia. However, the vast majority of medicinal...
21 Apr 22 | AU | Australia’s TGA granted orphan drug designation to Roche’s glofitamab. The TGA also provided...
14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free...
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and...
Thank you to all our clients who participated in the inaugural 2022 Pearce IP “We Hear You” survey. The responses we...
31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising...